ADT in High-Risk Prostate Cancer: How to Advise Patients?
Dr. Gerald Chodak interprets findings from a new study comparing 18-month vs 36-month hormone therapy in high-risk prostate cancer patients.
Source: Medscape Urology Podcast - Category: Urology & Nephrology Authors: Medscape Source Type: podcasts
More News: Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Podcasts | Prostate Cancer | Study | Urology & Nephrology